New oral anticoagulants in patients with cancer: Current state of evidence

American Journal of Therapeutics

Volumn 22, Issue 6, 2015, Pages 460-468

  Sardar, Partha ^a   Chatterjee, Saurav ^b   Herzog, Eyal ^b   Pekler, Gerald ^c   Mushiyev, Savi ^c   Pastori, Luciano J ^c   Visco, Ferdinand ^c   Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c METROPOLITAN HOSPITAL CENTER   (United States)

Author keywords

Apixaban; Cancer; Dabigatran; New oral anticoagulants; Rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN;

ARTICLE; BLEEDING; CANCER PATIENT; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; AGED; COMPLICATION; FEMALE; MALE; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RIVAROXABAN; VENOUS THROMBOEMBOLISM;

EID: 84947062279     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000055     Document Type: Article

References (20)

1. Siegal DM, Garcia D. Anticoagulants in cancer. J Thromb Haemost. 2012;10:2230-2241.
2. Weitz JI. Potential of new anticoagulants in patients with cancer. Thromb Res. 2010;125(Suppl 2):S30-S35.
3. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
4. Sørensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850.
5. Martin LK, Bekaii-Saab T: Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants? Thrombosis. 2012;2012:758385.
6. Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
7. Fox BD, Kahn SR, Langleben D, et al: Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012; 345:e7498.
8. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-2391.
9. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor beva-cizumab in cancer patients: a meta-analysis. JAMA. 2008; 300:2277-2285.
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;18:W65-W94.
11. Higgins JPT, Altman DG, Sterne JAC, eds. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (Updated March 2011). Available at: http://www.cochrane-handbook.org. Accessed 2 March, 2013.
12. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
13. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous throm-boembolism. N Engl J Med. 2010;363:2499-2510.
14. EINSTEIN-PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-1297.
15. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368: 513-523.
16. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
17. Schulman S, Kearon C, Kakkar AK, et al; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous throm-boembolism. N Engl J Med. 2013;368:709-718.
18. Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thrombo-embolism in patients with metastatic cancer. J Thromb Haemost. 2012;10:807-814.
19. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacoki-net. 2013;52:69-82.
20. Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs. 2012;72: 1739-1753.